Frank Scholz, PhD, president and COO of NorthStar.

Scholz joined NorthStar in June 2021, as senior vice president and COO. Prior to joining NorthStar, he was a managing director at AlixPartners, where he led the company's healthcare and life sciences practice.

In his new role, Scholz will be responsible for driving NorthStar's sales of existing and new products, including the therapeutic radioisotopes copper-67, actinium-225, and the SPECT imaging agent, FibroScint (technetium-99m F4A), NorthStar said.